|
A Study of a Combination of Four Drugs in Patients with Recent HIV Infection Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on A Study of a Combination of Four Drugs in Patients with Recent HIV Infection conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Study of a Combination of Four Drugs in Patients with Recent HIV Infection Clinical research trials and A Study of a Combination of Four Drugs in Patients with Recent HIV Infection healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as A Study of a Combination of Four Drugs in Patients with Recent HIV Infection. A Study of a Combination of Four Drugs in Patients with Recent HIV Infection Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Study of a Combination of Four Drugs in Patients with Recent HIV Infection clinical trial. Human subjects often receive the most effective healthcare possible for their A Study of a Combination of Four Drugs in Patients with Recent HIV Infection condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of a Combination of Four Drugs in Patients with Recent HIV Infection  A Study of a Combination of Four Drugs in Patients with Recent HIV Infection
A Study of a Combination of Four Drugs in Patients with Recent HIV Infection
For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: The purpose of this study is to see if it is safe to give a combination of four anti-HIV drugs to patients recently infected with HIV who have never received anti-HIV treatment. The effects of this combination of drugs on the immune system and the level of HIV in the body are studied also. The four-drug combination includes lamivudine, abacavir, amprenavir, and indinavir.
Details: Patients receive a four-drug regimen consisting of two nucleoside reverse transcriptase inhibitors (3TC and abacavir) and two protease inhibitors (amprenavir and indinavir) for a minimum of 48 weeks. At specified time points, patients undergo physical assessments and efficacy evaluations which include plasma HIV-1 RNA measurements and CD4 cell counts. Depending on the immunologic and virologic status of the patient, further testing may be done to determine whether quadruple drug therapy can attain undetectable viral levels.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 15 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed with caution and/or careful monitoring: - Drugs which may interact at CYP3A4 (e.g., alprazolam, carbamazepine, codeine, clarithromycin, dapsone, diazepam, diltiazem, erythromycin, estrogens, fluvastatin, glucocorticoids, imipramine, lidocaine, lovastatin, nifedipine, phenobarbital, phenytoin, simvastatin, and warfarin). - Drugs that inhibit cytosolic alcohol dehydrogenase (e.g., ethanol, disulfiram, chlorzoxazone, chlorpromazine, isoniazid, and chloral hydrate). - Drugs known to affect renal tubular secretion (e.g., probenecid or cimetidine), cause liver toxicity, or induce myelosuppression. Patients must have: - Documented and confirmed acute HIV-1 infection. - No prior exposure to antiretroviral treatment. - Ability to comply with the investigational nature of the study for a minimum of 48 weeks. - Consent of parent or guardian if under the age of 18. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - A clinical diagnosis of AIDS, excluding CD4+ cell counts less than 200/mm3. - A serious medical condition such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction that, in the opinion of the investigator, compromises the safety of the patient. - Institutionalized or mentally disabled. - Inability to comply with the dosing schedule and protocol evaluations for reasons other than those specified. Concurrent Medication: Excluded: - Concurrent therapy with rifampin, rifabutin, terfenadine, astemizole, ketoconazole, itraconazole, cisapride, triazolam, midazolam, quinidine, amiodarone, and/or ergotamine/dihydroergotamine-containing regimens. - Foscarnet or therapy with other agents with documented in vitro or in vivo activity against HIV-1. - Medications known to induce or inhibit hepatic cytochrome P450 enzyme systems. - Vitamin E supplements. Concurrent Treatment: Excluded: - Dependence on blood transfusions. - Other investigational treatments. Patients with the following prior conditions are excluded: - A history of clinically relevant pancreatitis or hepatitis within 6 months of study entry. - A history of inflammatory bowel disease or malignancy, intestinal ischemia, malabsorption, or other gastrointestinal dysfunction that might interfere with drug absorption or render the patient unable to take oral medication. - An unexplained fever above 38.5 Celsius for more than 14 days within 30 days of study entry. - A history of coagulopathy. Prior Medication: Excluded: - Prior exposure to antiretroviral therapy. - Therapy with immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide, anti-cytokine agents or interferons, cytotoxic chemotherapeutic agents, or anti-oxidants within 30 days of study entry. Prior Treatment: Excluded: Radiation therapy within 30 days of study entry. Risk Behavior: Excluded: Alcohol or illicit drug use which, in the opinion of the investigator, may interfere with ability to comply with the dosing schedule and protocol evaluations.
Total Enrollment: 30
Location and Contact Information:
Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ
New York City, New York, 10021
United States
Miriam Hosp / Family Healthcare Ctr at SSTAR
Providence, Rhode Island, 02906
United States
Additional Information:
Study ID Numbers: 264K; COLA 2012
Study Start Date:
Record last reviewed: June 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002233
Other Hiv Infections Studies:
1. Helping HIV Infected Patients in South Africa Adhere to Drug Regimens
2. Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding
3. A Phase I Trial of Tecogalan sodium ( DS-4152 ) Administered as an Infusion Weekly x 4
4. A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia
5. A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success with Itraconazole But Not with Fluconazole
Related Studies:
Other HIV Infections Clinical Trials
Other Rhode Island Clinical Trials
Other Providence Clinical Trials
A Study of a Combination of Four Drugs in Patients with Recent HIV Infection
|
|
|
|
|
|
|
|
